Loading stock data…
LivaNova PLC (LIVN)
$83.06-0.37 (-0.44%)
After Hours$83.06+0.00 (+0.00%)· Last close Jun 29
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LivaNova PLC in the Healthcare sector is trading at $83.06 with a market capitalization of $4.4B. Wall Street consensus targets $81.50 (10 analysts), implying a -1.9% move over the next 12 months. The stock is currently near its 52-week high of $83.98, remaining 31.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $362.26M↑ | $360.92M↑ | $357.75M↑ | $352.52M↑ | $316.86M |
| Gross Profit | $243.75M↑ | $239.77M↓ | $244.85M↑ | $238.99M↑ | $216.25M |
| Operating Income | $41.47M↓ | $42.58M↓ | $54.01M↓ | $54.18M↑ | $48.62M |
| Net Income | $22.29M↓ | $30.91M↑ | $26.78M↓ | $27.16M↑ | -$327.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switz...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.85%
Volume
Today's trading volume
960,317
Recent News
LivaNova Reports Improved OSA Outcomes With PolySync Programming
LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.
LivaNova (LIVN) Stock Valuation Check After Strong Recent Shareholder Returns
LivaNova stock reacts to recent performance metrics LivaNova (LIVN) has drawn fresh attention after recent performance metrics highlighted its position in medical technology, with the stock’s returns over the past month and past 3 months prompting closer investor scrutiny. See our latest analysis for LivaNova. The recent 1 day share price return of 1.99% and 90 day share price return of 36.74% come on top of a 1 year total shareholder return of 71.43%. This combination points to building...
LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why LivaNova (LIVN) Is Up 18.0% After Boosting 2026 Outlook And Winning Aura6000 FDA Approval
LivaNova PLC previously reported that first-quarter 2026 sales rose to US$362.26 million from US$316.86 million a year earlier, with net income improving to US$22.29 million from a very large net loss and basic earnings per share from continuing operations turning positive at US$0.41. Alongside beating adjusted earnings expectations and lifting full-year 2026 revenue and EPS guidance, LivaNova secured FDA premarket approval for its aura6000 System to treat moderate to severe obstructive...
LivaNova (LIVN) Q1 2025 Earnings Transcript
Briana Gotlin: Thank you, and welcome to our conference call and webcast discussing LivaNova's financial results for the first quarter of 2025. Joining me on today's call are Vladimir Makatsaria, our Chief Executive Officer and Member of the Board of Directors; Alex Shvartsburg, our Chief Financial Officer; Ahmet Tezel, our Chief Innovation Officer; Stephanie Bolton, President of Global Epilepsy; and Zach Glazier, Director of Investor Relations.